Yu Tommy Y, Gul Zartash, Hunt Alicia M, Williams Michael J, Maley Alexander M
Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA.
Department of Oncology, Aurora St. Luke's Medical Center, Milwaukee, USA.
Cureus. 2024 Aug 15;16(8):e66974. doi: 10.7759/cureus.66974. eCollection 2024 Aug.
Program death 1 (PD-1) inhibitors such as nivolumab are immune checkpoint inhibitors that have revolutionized the treatment of metastatic melanoma. Despite its success in treating melanoma, immune activation can lead to immune-related adverse effects, which are experienced by half of melanoma patients treated with PD-1 inhibitors. Despite the common frequency of immune-mediated adverse events, the development of a secondary lymphoma is exceedingly rare. We present the case of a 53-year-old woman diagnosed with stage IV metastatic melanoma, treated with nivolumab, who subsequently developed fatal subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
程序性死亡蛋白 1（PD-1）抑制剂，如纳武单抗，是免疫检查点抑制剂，它们彻底改变了转移性黑色素瘤的治疗方式。尽管其在治疗黑色素瘤方面取得了成功，但免疫激活可导致免疫相关不良反应，接受 PD-1 抑制剂治疗的黑色素瘤患者中有一半会出现这种情况。尽管免疫介导的不良事件很常见，但继发性淋巴瘤的发生极为罕见。我们报告了一例 53 岁女性，被诊断为 IV 期转移性黑色素瘤，接受纳武单抗治疗，随后发展为致命的皮下脂膜炎样 T 细胞淋巴瘤（SPTCL）。
